In another retrospective, an observational cohort study was performed to evaluate the reno-protective effects of DPP-4 inhibitors, urine albumin excretion, and eGFR, which were found to be significantly reduced after the administration of DPP-4 inhibitors in T2DM patients [32]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.